GlaxoSmithKline halted a late-stage clinical trial for its cancer therapy Tykerb after it exceeded its primary endpoint of time to disease progression. GSK will now move for regulatory approval for the drug in the second half of the year in Europe and the U.S. Researchers said that a combination therapy of Tykerb and capecitabine (Xeloda) versus capecitabine alone in women with advanced or metastatic breast cancer that have HER2 overexpression.
- read the AFX report [1]
Links:
[1] http://www.forbes.com/business/feeds/afx/2006/04/03/afx2641862.html